Urothelial Carcinoma
Advertisement
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
The nomogram is used preoperatively to determine the probability of nodal tropism.
Researchers assessed recurrence rates, overall survival, and disease progression.
Previous trials have revealed that neoadjuvant chemotherapy is an effective treatment path for patients with high-grade UTUC.
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Ferguson sheds light on a national analysis evaluating the role of lymph node dissection in patients with high-risk UTUC.
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Researchers analyzed the effects of NAC on complete and overall response as well as cancer-specific survival after RT.
Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States.
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Patients received 68Ga-FAP-2286 PET, and investigators recorded the SUVmax of 68Ga-FAP-2286 PET-positive lesions.
Dr. Birtle describes the utility of carboplatin versus cisplatin in this regimen and discusses metastasis-free survival.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.